Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600E PDGFRB over exp |
| Therapy | XL888 |
| Indication/Tumor Type | melanoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E PDGFRB over exp | melanoma | sensitive | XL888 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment with XL888 increased apoptosis and decreased growth of Zelboraf (vemurafenib)-resistant human melanoma cell lines harboring a BRAF V600E mutation and over expression of PDGFRB in cell culture and in xenograft models (PMID: 22351686). | 22351686 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (22351686) | The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. | Full reference... |